Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Medtech Contracting And Liability Changes From 1 June

Executive Summary

China has amended its 2014 primary regulation governing medical devices. The new version of the Regulation on Supervision and Administration of Medical Devices comes into force on 1 June, says Todd Liao of Morgan Lewis.

You may also be interested in...



China's Medtech Regulatory Update Does Not Go Far Enough For Overseas Innovators

Foreign medical device innovators accessing the Chinese market remain at a disadvantage to local companies, even after the recent regulatory pathway revision.

China Issues Raft Of Regulatory Notices: Guidelines, Standards And More Reforms

The January 2019 Asian Medtech Associations Regulatory Networking discussions focus on the volume of activity within China’s agencies in issuing guidances, technical standards, and in review updates. This series is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel